An effective response of the immune system’s “killer” T cells against infection with HIV may depend on exactly which viral protein is targeted, according to an international group of researchers. A new study finds that HIV-infected individuals in whom virus-specific CD8 T cells are targeted against the Gag protein have lower viral levels than do those with CD8 responses directed against other viral proteins.
When it comes to an immune response against HIV, research funded by the Wellcome Trust in the UK and the National Institutes of Health in the US has found that bigger is not necessarily better, contrary to conventional medical wisdom. The research may have a profound impact on the development of a vaccine against the disease.
The number of people living with HIV in the Middle East and North Africa has risen to 460,000 and some 68,000 people were newly infected in 2006 alone. In a bid to curb the region?s growing epidemic, countries have been working with UNAIDS to secure additional funding to scale-up the AIDS response in the region.
UNAIDS welcomes the report published in BioMed Central Medicine concerning a large and high-quality study in the Guntur district in the south Indian state of Andhra Pradesh. It contributes to a better understanding of the distribution of HIV in India?s enormous and diverse population although it is based on just one district.
The Joint United Nations Programme on HIV/AIDS and its Cosponsors, WHO, UNFPA, UNICEF and the World Bank, note with considerable interest today?s announcement by the US National Institutes of Health that two trials assessing the impact of male circumcision on HIV risk are being stopped on the recommendation of the NIH Data Safety and Monitoring Board (DSMB).
Acting swiftly after a survey by a government hospital said majority of girls did not practise safe sex, the administration here installed condom vending machines in different parts of the city in its bid to sensitise the vulnerable population against AIDS.
Imminent arrival of latest HIV drug darunavir, when combined with FUZEON, will give treatment-experienced patients a better chance to achieve undetectable viral load.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced an early end to two clinical trials of adult male circumcision because an interim review of trial data revealed that medically performed circumcision significantly reduces a man’s risk of acquiring HIV through heterosexual intercourse.
The International AIDS Vaccine Initiative (IAVI) issued this statement today following a National Institutes of Health (NIH) decision to end two clinical trials of adult male circumcision in Uganda and Kenya. The NIH’s Data Safety and Monitoring Board (DSMB), reviewing interim data, found that medically performed circumcision significantly protected men in the trial from HIV infection.
Government is not considering banning sale of Gutka in the country, Minister of State for Health and Family Welfare Panabaka Lakshmi said today.